우정바이오

215380KOSDAQ자연과학 및 공학 연구개발업

51.0 / 100

Reference Date: 2026-07-24

Financial Score13.5 / 40

News Sentiment12.5 / 25

Momentum15.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Rose 14.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Ujeong Bio operates in two main business areas: Bio Business and Infection Control Business, offering services such as biological indicator (BI) testing, genetic toxicity evaluation, and SPR analysis. The biotech industry is growing rapidly due to advancements in oncology drugs, immunotherapy, and obesity treatments, supported by government initiatives and increasing demand for pharmaceutical innovation.

Number of Employees

127people

Average Salary

50.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

1.84Industry Average 2.525.5Point

Lower than industry avg (good)

ROE

-21.03Industry Average -32.093.5Point

Below industry avg

Debt Ratio

142.65Industry Average 7.310.0Point

19.5x industry avg (risky)

Trend 2023~20250.5 / 10 points

Revenue Growth Rate

0.5 / 3

Avg ▼0.6% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼89.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -13.2% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50

Neutral
우정바이오, '콜마바이오텍'으로 사명 변경
우정바이오의 사명 변경은 브랜드 가치 제고를 위한 조치로, 직접적인 재무 영향은 제한적임을 시사합니다.

Detailed Momentum

52-week position5.0Point

52w mid range (47%)

Current 2,550Won52-week high 3,60552-week low 1,590

1-month return5.0Point

1m +14.86% (rising)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral[기재정정]주요사항보고서(회사합병결정)2026-07-21
Neutral주요사항보고서(회사합병결정)2026-07-20
Neutral임시주주총회결과2026-07-08
Neutral상호변경안내2026-07-08
Neutral본점소재지변경2026-07-08